ClinicalTrials.gg
Active, not recruitingNCT07203118Updated Oct 2, 2025

A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B

A Phase 2/3 interventional study of HTS 20mg and HTS 30mg in Chronic Hepatitis B, sponsored by Xi'an Xintong Pharmaceutical Research Co.,Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Xi'an Xintong Pharmaceutical Research Co.,Ltd. · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,444
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic — 5 open to participants now, 10 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B, Chronic.

Planned enrollment
2nd of 26
1,444 · median 124
Started
2025
the only one that year
Phase 2/3
Only one
of the 26
Registered
25th of 26
by date

Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2/3, and was the 25th registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

5 of the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

UsingTAF as the control, the nvestigators aim to further explore the efficacy and safety of different dosages of HTS in the treatment of patients with chronic hepatitis B; ultimately, the nvestigators determine the optimal recommended dosage of HTS to provide a basis for Phase III confirmatory clinical research.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1)Age between 18 to 65 years old (inclusive), regardless of gender. 2) Meets diagnostic criteria for chronic (documented HBsAg positivity or HBV DNA positivity for more than 6 months, or confirmed by liver histopathology).

3)No prior treatment with any nucleos(t)ide analogue oral antiviral therapy; or, previous treatment with any nucleos(t)ide analogue must have ended at least 6 months prior to baseline.

4) Any interferon therapy (both pegylated and non-pegylated) must be completed at least 1 year prior to baseline visit.

5) Willing to use effective non-pharmacological during the trial period.

Exclusion criteria

Exclusion Criteria:

  1. Hypersensitive to the study drug, its metabolites or any in its formula;
  2. With previous or present clinical hepatic decompensation (e.g., ascites, hepatic encephalopathy or varicose vein haemorrhage)
  3. Complicated with liver diseases, including chronic alcoholic hepatitis, drug-induced hepatitis, etc.
  4. Complicated with , or HDV infections
  5. Documented resistance to the antiviral drug (Tenofovir).
  6. Any cardiovascular, hematologic,pulmonary or nervous diseases deemed serious by the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,444 participants (estimated)

Study arms

  • Experimental
    HTS 20mg

    Drug: HTS 20mg

  • Experimental
    HTS 30mg

    Drug: HTS 30mg

  • Experimental
    HTS 40mg

    Drug: HTS 40mg

  • Experimental
    TAF 25mg

    Drug: TAF 25mg

Interventions

  • DrugHTS 20mg

    Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.

  • DrugHTS 30mg

    Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.

  • DrugHTS 40mg

    Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.

  • DrugTenofovir alafenamideStudies of Tenofovir alafenamideTenofovir alafenamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Once daily, administered concomitantly with one HTS placebo tablet per dose, taken once daily with or within 30 minutes after a meal.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events of the Optimal Dosing Regimen as assessed by CTCAE v5.0

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Oct 2, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Feb 28, 2030
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07203118
Lead sponsor
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Jul 1, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Feb 28, 2030 (estimated)
Last update
Oct 2, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion